Skip to content

A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01569802
Enrollment
10000
Registered
2012-04-03
Start date
2012-01-31
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer screening, tomosynthesis, FFDM

Brief summary

The primary aim of this study is to measure, document and compare recall rates of two-dimensional plus three dimensional (2D plus 3D) (Tomosynthesis) mammography to that of 2D mammography in a screening population. This study will compare recall rates for both non-cancer and cancer cases.

Interventions

None listed

Sponsors

Hologic, Inc.
CollaboratorINDUSTRY
Rose Imaging Specialists, P.A.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject is female of any race and ethnicity * The subject is asymptomatic and presents for routine screening mammography and chooses to have a combination 2D + 3D mammogram as her standard of care.

Exclusion criteria

* Patient chooses standard 2D mammography over a combination 2D + 3D mammogram

Design outcomes

Primary

MeasureTime frameDescription
Recall Rateup to 1 yearmeasure, document and compare recall rates of two-dimensional plus three dimensional (2D plus 3D) (Tomosynthesis) mammography to that of 2D mammography in a screening population

Secondary

MeasureTime frame
Cancer detection Rateup to 1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026